Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × utomilumab × Breast × Clear all
NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting
145 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled 15 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡